Tauros: Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

• Sponsor: Noscira SA (Industry)
• Overall Status: Completed
• CT.gov ID: NCT01049399
• Collaborator: i3 Research (Industry)
• Enrollment: 146
• Locations: 24
• Arms: 3
• Duration (Months): 23
• Patients Per Site: 6.1
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy

Condition or Disease	Intervention/Treatment	Phase
Progressive Supranuclear Palsy	Drug: tideglusib; Drug: tideglusib; Drug: placebo	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 146 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
• Study Start Date: Dec 1, 2009
• Actual Primary Completion Date: Sep 1, 2011
• Actual Study Completion Date: Nov 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo once daily administration of powder for oral suspension.	Drug: placebo; powder for oral suspension administered once daily in fasting conditions for 52 weeks
Experimental: NP031112 800 mg Group dosed with 800 mg once daily for 52 weeks	Drug: tideglusib; 800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks; Other Names: NP031112
Experimental: NP031112 600 mg Group treated with 600 mg once daily for 52 weeks	Drug: tideglusib; 600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks; Other Names: NP031112

Outcome Measures

Primary Outcome Measures

1. The change from Baseline between the 2 active study medication groups compared with the placebo group in the Progressive Supranuclear Palsy Rating Scale of Golbe [52 weeks]

Secondary Outcome Measures

1. Number of AEs and patients with an incidence rate of ≥ 5% AEs [52 weeks]

2. Change from Baseline between 2 active study medication groups vs placebo group in Modified Schwab and England Scale [52 weeks]

3. Change from Baseline between 2 active study medication groups vs placebo group in Timed Up and Go Test (quantitative motor function) [52 weeks]

4. Change from Baseline between 2 active study medication groups vs placebo group in cognitive function(Dementia Rating Scale-2,Frontal Assessment Battery,category and letter verbal fluency) [52 weeks]

5. Change from Baseline between 2 active study medication groups vs placebo group in Starkstein Apathy Scale (behavior) [52 weeks]

6. Change from Baseline between 2 active study medication groups vs placebo group in functional assessments(Unified Parkinson Disease rating Scale part II and European Quality of Life questionnaire) [52 weeks]

7. Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Change [52 weeks]

8. Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Severity [52 weeks]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 40 Years to 85 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Men and women with diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP (Appendix 1).

2. Age of 40 to 85 years (patients over 85 years could be included after previous assessment by Investigator and approved by sponsor).

3. Brain magnetic resonance imaging (MRI) study within 24 months before Baseline visit excluding other potential causes of parkinsonism, especially cerebrovascular lesions and space occupying lesions.

4. Mild-to-moderate stage of disease severity according to score of 1 to 4 in Golbe Staging System.(Appendix 2)

5. Female patients must be surgically sterilized; at least 1 year postmenopausal (confirmed by follicle-stimulating hormone [FSH] >20 international units [IUs]); using adequate birth control (implants, injectables, combined oral contraceptives, intrauterine contraceptive device, total sexual abstinence during the study or vasectomised partner). Male patients must be willing to use barrier contraception (condom) during the study and for 6 months after last treatment administration.

In European arms of study female patients must be without childbearing potential.

1. Caregiver (or dedicated nurse) living in same household or interacting with patient for >4 hours every day able to assure correct preparation and administration of study drug.

2. Patients living at home or in retirement home not requiring continuous nursing care.

3. General health status acceptable for participation in 64-week clinical trial.

4. Ability to swallow 100 mL of water suspension.

5. Any concomitant medication for PSP must be well-tolerated and unchanged for at least 1 month prior to Baseline visit and its dose and regimen should be maintained during study if there are no clinical reasons to modify it.

6. Occupational, physical, respiratory, or speech therapy is allowed but it must be stable for at least 1 month prior to screening.

7. Pharmacological treatment of any other chronic condition must be stable and well-tolerated for at least 1 month prior to screening. Analgesics, occasional per request nonsteroidal anti-inflammatory agents, and treatments for transient or emergent conditions are allowed.

8. Signed informed consent by patient and permitted prior to initiation of any study-specific procedure.

Exclusion Criteria:

1. Failure to perform screening or baseline examinations.

2. Hospitalization or change of chronic concomitant medication 1 month prior to or during screening period (apart from pre-planned hospitalization for a condition, which did not deteriorate since 1 month prior to screening period).

3. Clinical, laboratory or neuroimaging findings consistent with:

• other primary degenerative diseases such as Parkinson's disease; dementia with Lewy bodies; corticobasal degeneration; frontotemporal dementia; multiple system atrophy; parkinsonism-dementia complex of Guam, Kii or Guadeloupe; Alzheimer's disease; amyotrophic lateral sclerosis; Creutzfeldt-Jakob Disease; Huntington's disease; Down's syndrome; etc.

• cerebrovascular disease as major, strategic or multilacunar infarcts, or extensive white matter lesions scoring 3 in the Wahlund's scale [Wahlund et al., 2001].

• other central nervous system diseases (hydrocephalus, severe head trauma, tumours, subdural haematoma or other relevant space occupying processes, etc.).

• epilepsy.

• other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, clinically significant serum electrolyte disturbances, juvenile onset diabetes mellitus, etc.).

1. A current Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnosis of active major depression, schizophrenia or bipolar disorder.

2. Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations, may bias clinical or mental assessment or put patient at special risk, such as:

• chronic liver disease, as indicated by liver function test abnormalities (ALAT, ASAT, bilirubin or GGT out of range) positive serology for Hepatitis C, or other manifestations of liver disease

• respiratory insufficiency

• renal insufficiency (serum creatinine >2 mg/dL (>150 micromol/L) and creatinine clearance <60 (according to Cockcroft-Gault formula)

• heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before screening).

• bradycardia (heart beat <50/min) or tachycardia (heart beat >95/min)

• episodes of unstable or uncontrolled hypertension (systolic pressure >160 mm Hg or diastolic pressure >100 mm Hg) or hypotension (systolic pressure <90 mm Hg or diastolic pressure <45 mm Hg) during 2 months prior to Baseline visit.

• atrioventricular block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF interval (males >450 msec and females >470 msec using Fridericia's formula: QTc = QT/cube root of RR).

• uncontrolled diabetes mellitus.

• malignant tumors within last 5 years except skin malignancies (other than melanoma) or indolent prostate cancer.

• metastases.

1. Disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, and severe language difficulty).

2. Chronic daily drug intake of:

• drugs metabolized by cytochrome P450 (CYP)3A4 with narrow therapeutic window (acenocoumarol, warfarin, and digitoxin)

• anticonvulsants indicated for epileptic seizures

• systemic anticholinergics with relevant action on central nervous system

• acetylcholinesterase inhibitors

• neuroleptics except quetiapine, clozapine or other atypical neuroleptics

• nootropics such as piracetam, propentofylline, hydergine, vinpocetine, ginkgo biloba, coenzyme Q-10, idebenone and derivatives

• centrally active anti-hypertensive drugs such as clonidine, alpha methyl dopa, guanidine, and guanfacine

• systemic cortico-steroids or immunosuppressants

• systemic nonsteroidal anti-inflammatory agents (except taken as occasional medication per request or acetylsalicylic acid up to 100 mg/day as an antiplatelet agent).

• memantine, lithium, valproic acid or other GSK-3 inhibitors within 3 months prior to the Baseline visit.

1. Suspected or known history of drug abuse or excessive alcohol intake*

2. Suspected or known allergy to any components of study treatments.

3. Enrollment in another investigational drug study within 3 months before Baseline visit.

4. Any condition, which in the opinion of Investigator makes patient unsuitable for inclusion or likely to be non-compliant.

• More than 21 units per week for men and 14 for women; or consumption of more than 8 units in a single episode. 1 unit equals approximately 1 glass of wine, 250 ml of beer or 1 shot (25 ml) of spirit.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Parkinson's and Movement Disorder Institute	Fountain Valley	California	United States	92708
2	Department of Neurology, David Geffen School of Medicine at UCLA	Los Angeles	California	United States	90095
3	Mayo Clinic Jacksonville	Jacksonville	Florida	United States	32224
4	University of South Florida 5	Tampa	Florida	United States	33606
5	Division of Movement Disorders, University of Louisville	Louisville	Kentucky	United States	40202
6	University of Medicine and Dentistry, Robert Wood Johnson Medical School	New Brunswick	New Jersey	United States	08901
7	Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson Beelitz	Beelitz-Heilstätten		Germany	14547
8	Humboldt Universitat Charite, Campus Virchow, Neurologisch	Berlin		Germany	13353
9	Universitatsklinikum Carl-Guslav-Carus, Technische Universitat Dresden, Klinik und Poliklinik fur Neurologie	Dresden		Germany	01307
10	Medizinische Hochschule Hannover, Neurologie 0E 7210	Hannover		Germany	30625
11	Zentrum fur Nervenheilkunde. Klinik fur Neurologie mit Poliklinik.	Marburg		Germany	35039
12	University Hospital Tuebingen,Eberhard-Karls-Universitat, Universitatsklinikum Neurologie	Tubingen		Germany	72076
13	Hospital de Cruces	Barakaldo		Spain	48902
14	Fundació Ace	Barcelona		Spain	08014
15	Dpto.neurologia. H. Clinic.	Barcelona		Spain	08036
16	Dpt. Neurologia. Hospital Ramón y Cajal.	Madrid		Spain	28034
17	Hospital U. La Paz	Madrid		Spain	28046
18	Hospital Puerta del Hierro	Madrid		Spain	28222
19	Hospital de Donostia	San Sebastian		Spain	20014
20	Hospital Mutua Terrassa	Terrasa		Spain	8221
21	Departement of Neurology, Hospital La Fe	Valencia		Spain	460009
22	The Walton Centre for Neurology and Neurosurgery NHS Trust	Liverpool		United Kingdom	L9 7LJ
23	Reta Lila Weston Institute of Neurological Studies,Sara Koe PSP Research Centre	London		United Kingdom	WC1N 1PJ
24	Clinical Ageing Research Unit	Newcastle upon Tyne		United Kingdom	NE4 5PL

Sponsors and Collaborators

• Noscira SA
• i3 Research

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Noscira SA
• ClinicalTrials.gov Identifier: NCT01049399
• Other Study ID Numbers: NP031112-08B02
• First Posted: Jan 14, 2010
• Last Update Posted: Jan 5, 2012
• Last Verified: Jan 1, 2012

• Additional relevant MeSH terms: Supranuclear Palsy, Progressive

Study Results

No Results Posted as of Jan 5, 2012